US equities |
NVDA $204.64 ▼-4.22% INTC $65.76 ▼-28.58% MU $884.74 ▼-5.30% AMZN $240.35 ▼-1.41% AAPL $344.63 ▼-1.23% SNDK $1,150.89 ▼-13.47% AMD $504.80 ▼-10.88% MSFT $521.91 ▼-1.55%
FinancialContent

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

27.28 +0.42 (+1.56%)
Delayed Quote Updated: 4:00 PM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
34 35 Next >
News headline image
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday ↗
Via The Motley Fool
News headline image
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
News headline image
3 Mid-Cap Stocks That Could Take Off in 2025 ↗
Via The Motley Fool
News headline image
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst ↗
JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights. 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 5 Years ↗
 
Via Benzinga
News headline image
Looking Into Viking Therapeutics's Recent Short Interest ↗
 
Via Benzinga
News headline image
$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
1 Under-the-Radar Stock to Buy Before It Soars by 156%, According to Select Wall Street Analysts ↗
This is a high-risk, high-reward stock. 
Via The Motley Fool
News headline image
Why Viking Therapeutics Stock Plummeted by 24% in December ↗
Via The Motley Fool
News headline image
Should You Buy the Dip on This High-Flying Stock? ↗
Via The Motley Fool
News headline image
StoryTrading's Secrets To January Gains - Don’t Miss These Picks ↗
As we usher in the new year, market dynamics continue to be shaped by a blend of tax-deferral selling, the January effect, and macro uncertainties. 
Via Talk Markets
Topics Stocks / Equities
News headline image
3 Stocks That Could Be Monster Winners in 2025 ↗
Via The Motley Fool
News headline image
Down 18% in 1 Day, Is Viking Therapeutics Stock in Trouble Due to Merck? ↗
Via The Motley Fool
News headline image
My Top 10 Stocks to Buy for 2025 ↗
Via The Motley Fool
News headline image
Why Viking Therapeutics Tumbled by More Than 10% This Week ↗
Via The Motley Fool
News headline image
Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up ↗
Today's sell-off in Novo Nordisk may be the buying opportunity you've been waiting for. 
Via The Motley Fool
News headline image
Stock Market Tumbles, Treasury Yields Soar On Fed Rate Outlook: Weekly Review ↗
Micron, Vertex, Novo Nordisk and Nike were notable losers on news. 
Via Investor's Business Daily
Topics Economy
News headline image
Novo Nordisk Dives On CagriSegma Obesity Drug Trial. Eli Lilly, Viking Jump. ↗
Eli Lilly and Viking Therapeutics jumped on Novo's setback. 
Via Investor's Business Daily
News headline image
From Powell To Profits: Strategic Stock Picks Amid Market Uncertainty ↗
Yesterday's market movement aligned perfectly with expectations, as the FOMC meeting drove significant volatility. 
Via Talk Markets
Topics Stocks / Equities
News headline image
What's Going On With Viking Therapeutics Stock On Wednesday? ↗
Merck partners with Hansoh Pharma for GLP-1 drug development, while analysts highlight Viking's obesity assets as key for future growth. 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche ↗
Under the deal's terms, Hansoh Pharma receives $112 million up front and a potential $1.9 billion in milestone payments. 
Via Investor's Business Daily
News headline image
9 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf? ↗
The weight-loss drugs space continues to heat up. Here's the latest news from the segment. 
Via Investor's Business Daily
News headline image
Prediction: These Could Be the Best-Performing Pharma and Biotech Stocks Through 2030 ↗
Via The Motley Fool
News headline image
2 Soaring Stocks That Could Climb 68% to 166% Higher in 2025, According to Wall Street ↗
Via The Motley Fool
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Warning: This Skyrocketing Stock Has a Hidden Risk ↗
Via The Motley Fool
News headline image
Should You Forget Pfizer and Buy These Unstoppable Stocks Instead? ↗
Via The Motley Fool
News headline image
After Crashing 27% in the Past Month, Is Viking Therapeutics Stock a Bargain Buy Right Now? ↗
Via The Motley Fool
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
34 35 Next >